NPJ Breast Cancer最新文献

{"title":"Enabling DCIS subtyping: leveraging foundation models for robust grading and molecular biomarker scoring.","authors":"S Doyle, M A Oerlemans, J Brunekreef, E Marcus, L Mulder, Y Liu, I Bouybayoune, E J Sawyer, A M Thompson, S E Pinder, Jelle Wesseling, Alastair Thompson, Serena Nik-Zainal, Elinor J Sawyer, Helen Davies, Andrew Futreal, Nicholas Navin, E Shelley Hwang, Jos Jonkers, Jacco van Rheenen, Fariba Behbod, Esther H Lips, Marjanka Schmidt, Lodewyk F A Wessels, Daniel Rea, Proteeti Bhattacharjee, Hilary Stobart, Deborah Collyar, Donna Pinto, Ellen Verschuur, Marja van Oirsouw, C I Sánchez, J Teuwen, J Wesseling, E H Lips","doi":"10.1038/s41523-026-00957-6","DOIUrl":"https://doi.org/10.1038/s41523-026-00957-6","url":null,"abstract":"<p><p>Ductal Carcinoma In Situ (DCIS) is a non-obligate precursor of invasive breast cancer. Due to a lack of reliable prognostic markers, nearly all women with DCIS undergo intensive treatment-often unnecessarily. The LORD trial addresses this by offering active surveillance to women with screen-detected, ER-positive, HER2-negative, grade 1 or 2 DCIS, aiming to reduce overtreatment. To support this, we developed a deep learning pipeline based on foundation models to predict grade, ER, and HER2 status directly from H&E-stained digitized pathology slides. Models were trained and tested on a Dutch multicenter dataset (n = 887) and externally validated on a UK dataset (n = 259). On the Dutch data, the models achieved mean AUROCs of 0.90 (ER), 0.84 (HER2), and 0.86 (grade); external validation yielded 0.80, 0.74, and 0.75, respectively. Using these outputs, we stratified patients according to active surveillance criteria, reaching balanced accuracies of 0.81 (Dutch) and 0.64 (UK), with corresponding NPVs of 0.86 and 0.76. Our models generalize across cohorts and reliably predict key biomarkers, supporting the identification of DCIS patients eligible for less aggressive management.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147840776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Co-occurring rare germline DNA repair gene variants in BRCA1/BRCA2 implicated hereditary breast cancer families.","authors":"Wejdan M Alenezi, Neil Recio, Caitlin T Fierheller, Corinne Serruya, Timothée Revil, Anne-Marie Mes-Masson, Diane Provencher, Celia M T Greenwood, Jiannis Ragoussis, Patricia N Tonin","doi":"10.1038/s41523-026-00956-7","DOIUrl":"https://doi.org/10.1038/s41523-026-00956-7","url":null,"abstract":"<p><p>As gene-panels expand to include candidate breast cancer predisposing genes (CPGs) involved in diverse DNA repair pathways, we investigated an index breast cancer (BC) case from 56 BRCA1/BRCA2 implicated high-risk hereditary BC families using gene-based approach for co-occurring, rare germline variants predicted to be damaging and clinically relevant in 276 DNA repair genes (DRGs). Using whole exome sequencing analyses, we identified a total of 287 variants in 55% of DRGs, of which 24 loss-of-function and 36 other predicted damaging variants were identified in 72% and 76% of BRCA1 and BRCA2 implicated cases, respectively. We also identified 60 variants of clinical interest in various known CPGs, including those involved in risk to other cancers, in 72% of BRCA1 and 60% of BRCA2 cases. The number of variants predicted to be deleterious in diverse DRGs raises questions about the interpretability of findings as panel testing expands beyond clinically established breast CPGs.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147840750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imlunestrant with or without abemaciclib in advanced breast cancer: safety analyses from the EMBER-3 trial.","authors":"Joyce O'Shaughnessy, Francois-Clement Bidard, Patrick Neven, Monica Lis Casalnuovo, Philippe Aftimos, Cristina Saura, Nadia Harbeck, Lisa A Carey, Giuseppe Curigliano, Jose A Garcia-Saenz, Maria Fernandez Abad, Larissa de Paula, Yeon Hee Park, Ozgur Ozyilkan, Maria Munoz, Emily Barrett, Shanshan Cao, Aarti Chawla, Komal L Jhaveri","doi":"10.1038/s41523-026-00950-z","DOIUrl":"https://doi.org/10.1038/s41523-026-00950-z","url":null,"abstract":"<p><p>In EMBER-3 (NCT04975308), among patients with ER + , HER2- advanced breast cancer (ABC) with recurrence/progression on/after endocrine therapy (ET), imlunestrant significantly prolonged PFS versus standard ET in patients with ESR1 mutations, and imlunestrant + abemaciclib prolonged PFS versus imlunestrant in the overall population. We report the incidence, severity, timing, and management of common treatment-emergent adverse events (TEAEs), including safety profiles of select subgroups. In both imlunestrant-containing arms, the most common TEAEs were reversible, low grade, single occurrences; occurred early in treatment; and resulted in few treatment discontinuations (imlunestrant, 5%; imlunestrant + abemaciclib, 6%). TEAEs in imlunestrant+abemaciclib arm were managed with dose adjustments (61%) and supportive medication. Imlunestrant monotherapy had a similar safety profile between patients aged <65 and ≥65 years, while imlunestrant + abemaciclib had a similar safety profile to other abemaciclib+ET combinations in both age groups. Imlunestrant and imlunestrant + abemaciclib provide effective, convenient oral therapy with a favorable and manageable safety profile for patients with ER+, HER2- ABC with recurrence/progression on/after ET.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147777237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multimodal analysis of a rare BARD1 missense variant suggests its pathogenicity is conditional.","authors":"Fiona Chan-Pak-Choon, Yuandi Gao, José Camacho-Valenzuela, Júlia-Jié Cabré-Romans, Amisha Minju-Op, Lili Fu, Paz Polak, Barbara Rivera, Raquel Cuella-Martin, William D Foulkes","doi":"10.1038/s41523-026-00955-8","DOIUrl":"https://doi.org/10.1038/s41523-026-00955-8","url":null,"abstract":"<p><p>Hereditary breast cancer involves multiple risk genes, including BARD1, which confers low to moderate risk and is associated with triple-negative breast cancer (TNBC). We report a proband with a primary ER+/PR+/HER2- breast cancer, which recurred unilaterally as a TNBC and who later developed endometrial cancer. Clinical germline testing revealed a rare BARD1 missense variant of uncertain significance [c.2258G>T; p.(Gly753Val)]. Whole-exome sequencing of tumors and blood revealed BARD1 loss of heterozygosity and mutational signature 3 - indicative of homologous recombination (HR) repair deficiency - exclusively in the TNBC recurrence. Functional assays demonstrated impaired HR repair via increased PARP inhibitor sensitivity and reduced RAD51 foci formation. We hypothesize that the selective pressure exerted by tamoxifen resulted in breast cancer subtype switching and uncovered the pathogenic potential of the BARD1 p.(Gly753Val) variant. This case illustrates a previously unreported scenario where the pathogenicity of a germline BARD1 variant appears conditional on prior treatment.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147777158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and internal validation of mammography feature-based prognostic models for distant recurrence-free survival of invasive breast cancer in a screening cohort.","authors":"Jim Peters, Bas B L Penning de Vries, Jos A A M van Dijck, Ritse M Mann, Nikita Moriakov, Jonas Teuwen, Nico Karssemeijer, Esther H Lips, Jelle Wesseling, Merle M van Leeuwen, Alexandra W van den Belt-Dusebout, Carla H van Gils, Ruud Pijnappel, Linda de Munck, Marja van Oirsouw, Ellen Verschuur, Sjoerd G Elias, Mireille J M Broeders","doi":"10.1038/s41523-026-00946-9","DOIUrl":"https://doi.org/10.1038/s41523-026-00946-9","url":null,"abstract":"<p><p>Overdiagnosis in breast cancer screening may be reduced by identifying lesions that, although detected on screening mammograms, are unlikely to progress to poor outcomes and may not require recall. As a proof-of-concept, we evaluated prognostic models for 10-year distant recurrence-free survival (DRFS) using radiomics features from invasive breast cancers (IBCs) presenting as masses on screening mammograms. In a cohort of screened women, 1466 IBC patients with clinical, pathological, and follow-up data were identified through national registries. Using radiomics features, tumor volume, and specific growth rate, proportional hazards models were developed to predict 10-year distant recurrence risk. Models were trained using positive screening mammograms of patients with screen-detected IBC (n = 1063) and diagnostic mammograms of patients with interval cancer (n = 406). Performance was evaluated only in screen-detected IBCs using repeated nested cross-validation. Median follow-up was 5.1 years (10th-90th percentile: 2.1-10.1), with 111 distant recurrences within 10 years. Model performance was moderate (C-index 0.70 [SD 0.01], calibration slope 1.22 [SD 0.13]), with predicted 10-year recurrence risks ranging from 4.9% to 18.0% (10th-90th percentile). The 42 IBCs with the lowest predicted risk had a 10-year recurrence probability of 2.6% (95% CI 0-7.5%), of whom only five received adjuvant systemic therapy. These findings suggest that mammography-based radiomics features may help identify low-risk IBCs and potentially reduce overdiagnosis by reconsidering recall for selected cases.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147729651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of T-DXd-associated pulmonary toxicity in real-world settings and clinical trials.","authors":"Simon Udovica, Rupert Bartsch, Christian F Singer, Clemens Leitgeb, Maximilian Marhold, Christian Peters-Engl, Verena Sagaster, Maximilian Hochmair, Muna Ferner, Wolfgang Hilbe, Kathrin Strasser-Weippl","doi":"10.1038/s41523-026-00936-x","DOIUrl":"https://doi.org/10.1038/s41523-026-00936-x","url":null,"abstract":"<p><p>Interstitial lung disease (ILD) is a common and potentially life-threatening adverse event associated with trastuzumab deruxtecan (T-DXd). In the pivotal T-DXd clinical trials, 10-15% of patients developed ILD, with stringent mitigation strategies aimed at the early detection of low-grade cases. Real-world data are urgently needed to assess ILD incidence and outcomes outside controlled trial settings. This retrospective analysis included 190 patients treated with T-DXd at the Vienna Healthcare Group between August 2020 and December 2023. Among them, 17 (8.9%) developed any-grade ILD, with 8 cases (4.2% of the total cohort; 47.1% of ILD cases) classified as grade ≥3. The median time to ILD onset was 86 days, with a significantly shorter onset for high-grade compared to low-grade ILD (44.5 vs. 119 days, p = 0.01). A pooled real-world analysis (n = 1255, including patients from this study) demonstrated a higher incidence of high-grade ILD in real-world settings compared to phase III trials (2.9% vs. 1.4%, p = 0.014), despite no significant difference in overall ILD incidence (10.4% vs. 11.1%, p = 0.62). However, high-grade ILD rates in the real-world cohort were comparable to those reported in early phase I/II trials (2.9% vs. 3.5%, p = 0.41). These findings suggest a greater risk of high-grade ILD in real-world settings and underscore the need for rigorous patient selection, screening, and management strategies in clinical practice. Furthermore, the shorter onset of high-grade ILD suggests distinct pathophysiological mechanisms that warrant further investigation.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147717553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute circulating tumor DNA dynamics during and after systemic therapy initiation for advanced triple-negative breast cancer.","authors":"Briana To, Vishnu Prasath, Deloris Veney, Christian Rolfo, Viktor Adalsteinsson, William E Carson, Robert Wesolowski, Daniel Stover, Dionisia Quiroga","doi":"10.1038/s41523-026-00953-w","DOIUrl":"10.1038/s41523-026-00953-w","url":null,"abstract":"<p><p>Circulating tumor DNA (ctDNA) 'tumor fraction' (TF) may correlate with therapy response, but little is known regarding TF dynamics immediately after therapy initiation. Plasma samples from a single-arm clinical trial enrolling patients with triple-negative breast cancer were collected at a variety of time points following infusion of onalespib (day -7), paclitaxel (day 1), and onalespib + paclitaxel (day 8). 313 samples from 14 patients underwent shallow whole genome sequencing and TF determination. The primary objective was to evaluate TF change from pre-infusion to 6 h and 24 h post-infusion. There was significant TF decline from pre-infusion to 6 h for paclitaxel (p = 0.03) but no change for onalespib or onalespib+paclitaxel at 6hl. There was no ctDNA TF surge within minutes to 24 h of onalespib, paclitaxel, or combination, despite an overall decline in TF during the first therapy cycle. However, there was significant decline in TF from pre-infusion to D9 (16% to 6.5%, p = 0.004). These findings support further research on ctDNA dynamics immediately after therapy initiation.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147699266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Functional assays for BRCA1 and BRCA2 variant analysis: new tools and their applications.","authors":"Muthiah Bose, Elangoli Ebrahimkutty Faseela, Maria Rossing, Claus Storgaard Sørensen","doi":"10.1038/s41523-026-00949-6","DOIUrl":"https://doi.org/10.1038/s41523-026-00949-6","url":null,"abstract":"<p><p>Genetic variants perturbing BRCA1 and BRCA2 function are linked to hereditary breast and ovarian cancers. As BRCA1 and BRCA2 are critical for homologous recombination-mediated DNA repair, interpretation of variants of uncertain significance is essential. Here, we review established and emerging assays used to functionally characterize BRCA1 and BRCA2 variants and highlight the strengths and limitations of each approach, as well as their general relevance to variant classification and clinical applications.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147691378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor mutations predict HER2-targeted therapy resistance in primary HER2-positive breast cancer.","authors":"Marion T Van Mackelenbergh, Nicole Pfarr, Karsten Weber, Michael Untch, Christine Solbach, Andreas Schneeweiss, Paul Jank, Jens Blohmer, Denise Treue, Sabine Schmatloch, Annika Lehmann, Claus Hanusch, Theresa Link, Christine Sers, Vesna Bjelic-Radisic, Michael Hummel, Jens Huober, Wolfgang D Schmitt, Peter A Fasching, Bahriye Aktas, Kerstin Rhiem, Mattea Reinisch, Valentina Nekljudova, Carsten Denkert, Sibylle Loibl","doi":"10.1038/s41523-026-00948-7","DOIUrl":"10.1038/s41523-026-00948-7","url":null,"abstract":"<p><p>The presented study investigated the relevance of mutations in 17 cancer genes and response to neoadjuvant chemotherapy in two clinical cohorts of HER2+ breast cancer. 364 samples from HER2+ tumors of the neoadjuvant studies GeparTrio (no anti-HER2 treatment, n = 71) and GeparSepto (dual HER2 blockade and randomization for paclitaxel vs. nab-paclitaxel, n = 293) were analyzed by targeted next generation sequencing of hot spot regions of 17 genes. Mutations in TP53 (47.3%) and PIK3CA (23.9%) were most prevalent. EGFR, KRAS, NRAS, HRAS were combined to the MAPK module with 2.5% harboring mutations. In GeparSepto, the pCR rate was significantly lower in PIK3CA-mutant vs wild-type (wt) tumors (47.7% vs. 66.7%; p = 0.009). In patients treated with nab-paclitaxel, pCR rates were significantly lower in PIK3CA-mutated tumors compared to wt-tumors (38.7% vs. 72.0%; p = 0.001). In the GeparTrio cohort without neoadjuvant anti-HER2 therapy the pCR rate was 27.3% in the mutant cohort compared to 16.3% in the PIK3CA-wt cohort (p = 0.339). In HER2+ breast cancer, PIK3CA mutations were significantly associated with reduced response to dual HER2 blockade with pertuzumab+trastuzumab as well as reduced response to nab-paclitaxel. This reduction was not observed in GeparTrio without anti-HER2 therapy.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13079752/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147675317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer-Results from the prospective PRAEGNANT registry.","authors":"Manuel Hörner, Andreas Hartkopf, Nelson John, Philipp Ziegler, Lothar Häberle, Sabrina Uhrig, Chloë Goossens, Niklas Amann, Jan-Philipp Cieslik, Lara M Tretschock, Dominik Dannehl, Thomas M Deutsch, Moritz Dimpfl, Max Ehlert, Kathleen Eichstädt, Alexander Englisch, Melitta B Köpke, Annika Krückel, Theresa Link, Annika Müller, Kristin Reinhardt, Jonas Roth, Henning Schäffler, Lea Sych, Nikolas Tauber, Christian M Tegeler, Catharina Wichmann, Maggie Banys-Paluchowski, Henriette Princk, Achim Rody, Sara Y Brucker, Nina Ditsch, Johannes Ettl, Tanja Fehm, Carolin C Hack, Peyman Hadji, Alexander Hein, Wolfgang W Janni, Hans-Christian Kolberg, Diana Lüftner, Michael P Lux, Volkmar Müller, Florin-Andrei Taran, Hans Tesch, Diethelm Wallwiener, Frederik Marmé, Stephan Seitz, Erik Belleville, Laura L Michel, Markus Wallwiener, Peter A Fasching, Andreas Schneeweiss, Christian Maurer","doi":"10.1038/s41523-026-00947-8","DOIUrl":"10.1038/s41523-026-00947-8","url":null,"abstract":"<p><p>Germline BRCA1 and BRCA2 mutations enable targeted therapies in human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC). The two poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors olaparib and talazoparib were introduced into clinical practice in 2018. Limited evidence about their routine clinical use highlights the importance of this analysis. We provide a real-world analysis for PARP-inhibitor use in ABC patients treated within the prospective German PRAEGNANT registry (NCT02338167). 152 patients with ABC receiving a PARP-inhibitor were included. Real-world progression-free survival (rwPFS) and real-world overall survival (rwOS) were calculated for all patients using the Kaplan-Meier method. Subgroups (line of therapy, metastasis timing, hormone receptor (HR) status, treatment: olaparib, talazoparib, among others), germline BRCA1, BRCA2 and PALB2 mutations and adverse events (AEs) were analyzed. The median rwPFS was 6.2 months (95% CI, 4.8-7.9) and the median rwOS was 17.1 months (95% CI, 14.4-22.3). Line of therapy, HR status and treatment (olaparib versus talazoparib) appeared to especially affect both rwPFS and rwOS. Among patients with a reported germline mutation, 36.1% had a BRCA1, 62.9% a BRCA2 and 1.0% a PALB2 mutation. In summary, outcomes were comparable to those reported in pivotal trials despite later-line use of PARP-inhibitors in this analysis.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13087296/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147662864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}